カテゴリー： QYResearch, 世界, 医療/バイオ

世界の抗増殖薬市場インサイト及び予測（ミコフェノール酸モフェチル、ミコフェノール酸ナトリウム、アザチオプリン）

◆英語タイトル：Global Antiproliferative Drugs Market Insights, Forecast to 2028
	◆商品コード：QY22JLX09222 ◆発行会社（リサーチ会社）：QYResearch ◆発行日：2022年7月（※2025年版があります。お問い合わせください。） ◆ページ数：129 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後3営業日） ◆調査対象地域：グローバル ◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD4,900 ⇒換算￥744,800	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD7,350 ⇒換算￥1,117,200	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD9,800 ⇒換算￥1,489,600	見積依頼/購入/質問フォーム

★QYResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、抗増殖薬のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に抗増殖薬の世界市場のxxx％を占める「ミコフェノール酸モフェチル」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「診療所」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
抗増殖薬の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの抗増殖薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

抗増殖薬のグローバル主要企業には、Accord Healthcare、F. Hoffmann-La Roche、Novartis AG、Mylan N.V.、Astellas Pharma、Pfizer、Glenmark Pharmaceuticals Limited、Zydus Cadila、Bristol-Myers Squibb Company、GlaxoSmithKline、Sanofi、Allergan、AbbVie、Cipla、Johnson & Johnson Private Limited、Teva Pharmaceutical Industries、Veloxis Pharmaceuticals、Eli Lilly and Company、Lupin、AstraZenecaなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

抗増殖薬市場は、種類と用途によって区分されます。世界の抗増殖薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
ミコフェノール酸モフェチル、ミコフェノール酸ナトリウム、アザチオプリン

【用途別セグメント】
診療所、病院、その他

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 抗増殖薬製品概要
- 種類別市場（ミコフェノール酸モフェチル、ミコフェノール酸ナトリウム、アザチオプリン）
- 用途別市場（診療所、病院、その他）
- 調査の目的
・エグゼクティブサマリー
- 世界の抗増殖薬販売量予測2017-2028
- 世界の抗増殖薬売上予測2017-2028
- 抗増殖薬の地域別販売量
- 抗増殖薬の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別抗増殖薬販売量
- 主要メーカー別抗増殖薬売上
- 主要メーカー別抗増殖薬価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（ミコフェノール酸モフェチル、ミコフェノール酸ナトリウム、アザチオプリン）
- 抗増殖薬の種類別販売量
- 抗増殖薬の種類別売上
- 抗増殖薬の種類別価格
・用途別市場規模（診療所、病院、その他）
- 抗増殖薬の用途別販売量
- 抗増殖薬の用途別売上
- 抗増殖薬の用途別価格
・北米市場
- 北米の抗増殖薬市場規模（種類別、用途別）
- 主要国別の抗増殖薬市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの抗増殖薬市場規模（種類別、用途別）
- 主要国別の抗増殖薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の抗増殖薬市場規模（種類別、用途別）
- 主要国別の抗増殖薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の抗増殖薬市場規模（種類別、用途別）
- 主要国別の抗増殖薬市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの抗増殖薬市場規模（種類別、用途別）
- 主要国別の抗増殖薬市場規模（トルコ、サウジアラビア）
・企業情報
Accord Healthcare、F. Hoffmann-La Roche、Novartis AG、Mylan N.V.、Astellas Pharma、Pfizer、Glenmark Pharmaceuticals Limited、Zydus Cadila、Bristol-Myers Squibb Company、GlaxoSmithKline、Sanofi、Allergan、AbbVie、Cipla、Johnson & Johnson Private Limited、Teva Pharmaceutical Industries、Veloxis Pharmaceuticals、Eli Lilly and Company、Lupin、AstraZeneca
・産業チェーン及び販売チャネル分析
- 抗増殖薬の産業チェーン分析
- 抗増殖薬の原材料
- 抗増殖薬の生産プロセス
- 抗増殖薬の販売及びマーケティング
- 抗増殖薬の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 抗増殖薬の産業動向
- 抗増殖薬のマーケットドライバー
- 抗増殖薬の課題
- 抗増殖薬の阻害要因
・主な調査結果

Antiproliferative drugs are the type of immunosuppressive medication that works by blocking cell-cycle pathways, limiting the T- and B-cell proliferation and thereby lowering the cytotoxic response aimed at the cardiac allograft. It is also termed as antimetabolites. Immunosuppressants are a type of medication that helps to suppress the immune system’s response to foreign substances. These medications limit the immune response and safeguard the new organ and its function, prevent organ rejection. They’re most commonly used to prevent autoimmune illnesses such as arthritis, myasthenia gravis, Crohn’s disease, lupus, rheumatoid arthritis, and organ transplant rejections like kidney, liver, and heart transplants.
Market Analysis and Insights: Global Antiproliferative Drugs Market
The global Antiproliferative Drugs market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Mycophenolate Mofetil accounting for % of the Antiproliferative Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Clinic segment is altered to an % CAGR throughout this forecast period.
China Antiproliferative Drugs market size is valued at US$ million in 2021, while the North America and Europe Antiproliferative Drugs are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Antiproliferative Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Antiproliferative Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Antiproliferative Drugs market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Antiproliferative Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Antiproliferative Drugs market.
Global Antiproliferative Drugs Scope and Market Size
Antiproliferative Drugs market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Antiproliferative Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Mycophenolate Mofetil
Mycophenolate Sodium
Azathioprine
Segment by Application
Clinic
Hospital
Others
By Company
Accord Healthcare
F. Hoffmann-La Roche
Novartis AG
Mylan N.V.
Astellas Pharma
Pfizer
Glenmark Pharmaceuticals Limited
Zydus Cadila
Bristol-Myers Squibb Company
GlaxoSmithKline
Sanofi
Allergan
AbbVie
Cipla
Johnson & Johnson Private Limited
Teva Pharmaceutical Industries
Veloxis Pharmaceuticals
Eli Lilly and Company
Lupin
AstraZeneca
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

❖ レポートの目次 ❖

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antiproliferative Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Mycophenolate Mofetil
1.2.3 Mycophenolate Sodium
1.2.4 Azathioprine
1.3 Market by Application
1.3.1 Global Antiproliferative Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Antiproliferative Drugs Market Perspective (2017-2028)
2.2 Antiproliferative Drugs Growth Trends by Region
2.2.1 Antiproliferative Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Antiproliferative Drugs Historic Market Size by Region (2017-2022)
2.2.3 Antiproliferative Drugs Forecasted Market Size by Region (2023-2028)
2.3 Antiproliferative Drugs Market Dynamics
2.3.1 Antiproliferative Drugs Industry Trends
2.3.2 Antiproliferative Drugs Market Drivers
2.3.3 Antiproliferative Drugs Market Challenges
2.3.4 Antiproliferative Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antiproliferative Drugs Players by Revenue
3.1.1 Global Top Antiproliferative Drugs Players by Revenue (2017-2022)
3.1.2 Global Antiproliferative Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Antiproliferative Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antiproliferative Drugs Revenue
3.4 Global Antiproliferative Drugs Market Concentration Ratio
3.4.1 Global Antiproliferative Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antiproliferative Drugs Revenue in 2021
3.5 Antiproliferative Drugs Key Players Head office and Area Served
3.6 Key Players Antiproliferative Drugs Product Solution and Service
3.7 Date of Enter into Antiproliferative Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antiproliferative Drugs Breakdown Data by Type
4.1 Global Antiproliferative Drugs Historic Market Size by Type (2017-2022)
4.2 Global Antiproliferative Drugs Forecasted Market Size by Type (2023-2028)
5 Antiproliferative Drugs Breakdown Data by Application
5.1 Global Antiproliferative Drugs Historic Market Size by Application (2017-2022)
5.2 Global Antiproliferative Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Antiproliferative Drugs Market Size (2017-2028)
6.2 North America Antiproliferative Drugs Market Size by Type
6.2.1 North America Antiproliferative Drugs Market Size by Type (2017-2022)
6.2.2 North America Antiproliferative Drugs Market Size by Type (2023-2028)
6.2.3 North America Antiproliferative Drugs Market Share by Type (2017-2028)
6.3 North America Antiproliferative Drugs Market Size by Application
6.3.1 North America Antiproliferative Drugs Market Size by Application (2017-2022)
6.3.2 North America Antiproliferative Drugs Market Size by Application (2023-2028)
6.3.3 North America Antiproliferative Drugs Market Share by Application (2017-2028)
6.4 North America Antiproliferative Drugs Market Size by Country
6.4.1 North America Antiproliferative Drugs Market Size by Country (2017-2022)
6.4.2 North America Antiproliferative Drugs Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Antiproliferative Drugs Market Size (2017-2028)
7.2 Europe Antiproliferative Drugs Market Size by Type
7.2.1 Europe Antiproliferative Drugs Market Size by Type (2017-2022)
7.2.2 Europe Antiproliferative Drugs Market Size by Type (2023-2028)
7.2.3 Europe Antiproliferative Drugs Market Share by Type (2017-2028)
7.3 Europe Antiproliferative Drugs Market Size by Application
7.3.1 Europe Antiproliferative Drugs Market Size by Application (2017-2022)
7.3.2 Europe Antiproliferative Drugs Market Size by Application (2023-2028)
7.3.3 Europe Antiproliferative Drugs Market Share by Application (2017-2028)
7.4 Europe Antiproliferative Drugs Market Size by Country
7.4.1 Europe Antiproliferative Drugs Market Size by Country (2017-2022)
7.4.2 Europe Antiproliferative Drugs Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antiproliferative Drugs Market Size (2017-2028)
8.2 Asia-Pacific Antiproliferative Drugs Market Size by Type
8.2.1 Asia-Pacific Antiproliferative Drugs Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Antiproliferative Drugs Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Antiproliferative Drugs Market Share by Type (2017-2028)
8.3 Asia-Pacific Antiproliferative Drugs Market Size by Application
8.3.1 Asia-Pacific Antiproliferative Drugs Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Antiproliferative Drugs Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Antiproliferative Drugs Market Share by Application (2017-2028)
8.4 Asia-Pacific Antiproliferative Drugs Market Size by Region
8.4.1 Asia-Pacific Antiproliferative Drugs Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Antiproliferative Drugs Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Antiproliferative Drugs Market Size (2017-2028)
9.2 Latin America Antiproliferative Drugs Market Size by Type
9.2.1 Latin America Antiproliferative Drugs Market Size by Type (2017-2022)
9.2.2 Latin America Antiproliferative Drugs Market Size by Type (2023-2028)
9.2.3 Latin America Antiproliferative Drugs Market Share by Type (2017-2028)
9.3 Latin America Antiproliferative Drugs Market Size by Application
9.3.1 Latin America Antiproliferative Drugs Market Size by Application (2017-2022)
9.3.2 Latin America Antiproliferative Drugs Market Size by Application (2023-2028)
9.3.3 Latin America Antiproliferative Drugs Market Share by Application (2017-2028)
9.4 Latin America Antiproliferative Drugs Market Size by Country
9.4.1 Latin America Antiproliferative Drugs Market Size by Country (2017-2022)
9.4.2 Latin America Antiproliferative Drugs Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antiproliferative Drugs Market Size (2017-2028)
10.2 Middle East & Africa Antiproliferative Drugs Market Size by Type
10.2.1 Middle East & Africa Antiproliferative Drugs Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Antiproliferative Drugs Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Antiproliferative Drugs Market Share by Type (2017-2028)
10.3 Middle East & Africa Antiproliferative Drugs Market Size by Application
10.3.1 Middle East & Africa Antiproliferative Drugs Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Antiproliferative Drugs Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Antiproliferative Drugs Market Share by Application (2017-2028)
10.4 Middle East & Africa Antiproliferative Drugs Market Size by Country
10.4.1 Middle East & Africa Antiproliferative Drugs Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Antiproliferative Drugs Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Accord Healthcare
11.1.1 Accord Healthcare Company Details
11.1.2 Accord Healthcare Business Overview
11.1.3 Accord Healthcare Antiproliferative Drugs Introduction
11.1.4 Accord Healthcare Revenue in Antiproliferative Drugs Business (2017-2022)
11.1.5 Accord Healthcare Recent Developments
11.2 F. Hoffmann-La Roche
11.2.1 F. Hoffmann-La Roche Company Details
11.2.2 F. Hoffmann-La Roche Business Overview
11.2.3 F. Hoffmann-La Roche Antiproliferative Drugs Introduction
11.2.4 F. Hoffmann-La Roche Revenue in Antiproliferative Drugs Business (2017-2022)
11.2.5 F. Hoffmann-La Roche Recent Developments
11.3 Novartis AG
11.3.1 Novartis AG Company Details
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Antiproliferative Drugs Introduction
11.3.4 Novartis AG Revenue in Antiproliferative Drugs Business (2017-2022)
11.3.5 Novartis AG Recent Developments
11.4 Mylan N.V.
11.4.1 Mylan N.V. Company Details
11.4.2 Mylan N.V. Business Overview
11.4.3 Mylan N.V. Antiproliferative Drugs Introduction
11.4.4 Mylan N.V. Revenue in Antiproliferative Drugs Business (2017-2022)
11.4.5 Mylan N.V. Recent Developments
11.5 Astellas Pharma
11.5.1 Astellas Pharma Company Details
11.5.2 Astellas Pharma Business Overview
11.5.3 Astellas Pharma Antiproliferative Drugs Introduction
11.5.4 Astellas Pharma Revenue in Antiproliferative Drugs Business (2017-2022)
11.5.5 Astellas Pharma Recent Developments
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Antiproliferative Drugs Introduction
11.6.4 Pfizer Revenue in Antiproliferative Drugs Business (2017-2022)
11.6.5 Pfizer Recent Developments
11.7 Glenmark Pharmaceuticals Limited
11.7.1 Glenmark Pharmaceuticals Limited Company Details
11.7.2 Glenmark Pharmaceuticals Limited Business Overview
11.7.3 Glenmark Pharmaceuticals Limited Antiproliferative Drugs Introduction
11.7.4 Glenmark Pharmaceuticals Limited Revenue in Antiproliferative Drugs Business (2017-2022)
11.7.5 Glenmark Pharmaceuticals Limited Recent Developments
11.8 Zydus Cadila
11.8.1 Zydus Cadila Company Details
11.8.2 Zydus Cadila Business Overview
11.8.3 Zydus Cadila Antiproliferative Drugs Introduction
11.8.4 Zydus Cadila Revenue in Antiproliferative Drugs Business (2017-2022)
11.8.5 Zydus Cadila Recent Developments
11.9 Bristol-Myers Squibb Company
11.9.1 Bristol-Myers Squibb Company Company Details
11.9.2 Bristol-Myers Squibb Company Business Overview
11.9.3 Bristol-Myers Squibb Company Antiproliferative Drugs Introduction
11.9.4 Bristol-Myers Squibb Company Revenue in Antiproliferative Drugs Business (2017-2022)
11.9.5 Bristol-Myers Squibb Company Recent Developments
11.10 GlaxoSmithKline
11.10.1 GlaxoSmithKline Company Details
11.10.2 GlaxoSmithKline Business Overview
11.10.3 GlaxoSmithKline Antiproliferative Drugs Introduction
11.10.4 GlaxoSmithKline Revenue in Antiproliferative Drugs Business (2017-2022)
11.10.5 GlaxoSmithKline Recent Developments
11.11 Sanofi
11.11.1 Sanofi Company Details
11.11.2 Sanofi Business Overview
11.11.3 Sanofi Antiproliferative Drugs Introduction
11.11.4 Sanofi Revenue in Antiproliferative Drugs Business (2017-2022)
11.11.5 Sanofi Recent Developments
11.12 Allergan
11.12.1 Allergan Company Details
11.12.2 Allergan Business Overview
11.12.3 Allergan Antiproliferative Drugs Introduction
11.12.4 Allergan Revenue in Antiproliferative Drugs Business (2017-2022)
11.12.5 Allergan Recent Developments
11.13 AbbVie
11.13.1 AbbVie Company Details
11.13.2 AbbVie Business Overview
11.13.3 AbbVie Antiproliferative Drugs Introduction
11.13.4 AbbVie Revenue in Antiproliferative Drugs Business (2017-2022)
11.13.5 AbbVie Recent Developments
11.14 Cipla
11.14.1 Cipla Company Details
11.14.2 Cipla Business Overview
11.14.3 Cipla Antiproliferative Drugs Introduction
11.14.4 Cipla Revenue in Antiproliferative Drugs Business (2017-2022)
11.14.5 Cipla Recent Developments
11.15 Johnson & Johnson Private Limited
11.15.1 Johnson & Johnson Private Limited Company Details
11.15.2 Johnson & Johnson Private Limited Business Overview
11.15.3 Johnson & Johnson Private Limited Antiproliferative Drugs Introduction
11.15.4 Johnson & Johnson Private Limited Revenue in Antiproliferative Drugs Business (2017-2022)
11.15.5 Johnson & Johnson Private Limited Recent Developments
11.16 Teva Pharmaceutical Industries
11.16.1 Teva Pharmaceutical Industries Company Details
11.16.2 Teva Pharmaceutical Industries Business Overview
11.16.3 Teva Pharmaceutical Industries Antiproliferative Drugs Introduction
11.16.4 Teva Pharmaceutical Industries Revenue in Antiproliferative Drugs Business (2017-2022)
11.16.5 Teva Pharmaceutical Industries Recent Developments
11.17 Veloxis Pharmaceuticals
11.17.1 Veloxis Pharmaceuticals Company Details
11.17.2 Veloxis Pharmaceuticals Business Overview
11.17.3 Veloxis Pharmaceuticals Antiproliferative Drugs Introduction
11.17.4 Veloxis Pharmaceuticals Revenue in Antiproliferative Drugs Business (2017-2022)
11.17.5 Veloxis Pharmaceuticals Recent Developments
11.18 Eli Lilly and Company
11.18.1 Eli Lilly and Company Company Details
11.18.2 Eli Lilly and Company Business Overview
11.18.3 Eli Lilly and Company Antiproliferative Drugs Introduction
11.18.4 Eli Lilly and Company Revenue in Antiproliferative Drugs Business (2017-2022)
11.18.5 Eli Lilly and Company Recent Developments
11.19 Lupin
11.19.1 Lupin Company Details
11.19.2 Lupin Business Overview
11.19.3 Lupin Antiproliferative Drugs Introduction
11.19.4 Lupin Revenue in Antiproliferative Drugs Business (2017-2022)
11.19.5 Lupin Recent Developments
11.20 AstraZeneca
11.20.1 AstraZeneca Company Details
11.20.2 AstraZeneca Business Overview
11.20.3 AstraZeneca Antiproliferative Drugs Introduction
11.20.4 AstraZeneca Revenue in Antiproliferative Drugs Business (2017-2022)
11.20.5 AstraZeneca Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の抗増殖薬市場インサイト及び予測（ミコフェノール酸モフェチル、ミコフェノール酸ナトリウム、アザチオプリン）(Global Antiproliferative Drugs Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界の抗増殖薬市場インサイト及び予測（ミコフェノール酸モフェチル、ミコフェノール酸ナトリウム、アザチオプリン）

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp